CN113905735A - 神经激肽-1拮抗剂 - Google Patents

神经激肽-1拮抗剂 Download PDF

Info

Publication number
CN113905735A
CN113905735A CN202080040881.3A CN202080040881A CN113905735A CN 113905735 A CN113905735 A CN 113905735A CN 202080040881 A CN202080040881 A CN 202080040881A CN 113905735 A CN113905735 A CN 113905735A
Authority
CN
China
Prior art keywords
compound
alkyl
heteroaryl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080040881.3A
Other languages
English (en)
Other versions
CN113905735B (zh
Inventor
黄建
祝令建
邹洋
唐应刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Shengdi Pharmaceutical Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd, Shanghai Senhui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN113905735A publication Critical patent/CN113905735A/zh
Application granted granted Critical
Publication of CN113905735B publication Critical patent/CN113905735B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

式II所示化合物或其药学上可接受的盐，及其制备方法。式II所示化合物是神经激肽‑1受体的拮抗剂，可用于与神经激肽‑1受体有关的疾病的治疗，可避免药物的溶血作用，降低药物给药时的副作用。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080040881.3A 2019-06-28 2020-06-28 神经激肽-1拮抗剂 Active CN113905735B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910572272 2019-06-28
CN2019105722721 2019-06-28
CN2019113752625 2019-12-27
CN201911375262 2019-12-27
PCT/CN2020/098460 WO2020259675A1 (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Publications (2)

Publication Number Publication Date
CN113905735A true CN113905735A (zh) 2022-01-07
CN113905735B CN113905735B (zh) 2024-03-15

Family

ID=74059657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080040881.3A Active CN113905735B (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Country Status (11)

Country Link
US (1) US20220380393A1 (zh)
EP (1) EP3991730A4 (zh)
JP (1) JP2022539570A (zh)
KR (1) KR20220054287A (zh)
CN (1) CN113905735B (zh)
AU (1) AU2020308397A1 (zh)
BR (1) BR112021026554A2 (zh)
CA (1) CA3144247A1 (zh)
MX (1) MX2021015827A (zh)
TW (1) TW202115064A (zh)
WO (1) WO2020259675A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116472048A (zh) * 2020-12-25 2023-07-21 上海盛迪医药有限公司 Nk1拮抗剂前药化合物与5-ht3受体拮抗剂的联用用途
WO2023134723A1 (zh) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种神经激肽-1拮抗剂前药化合物的晶型
WO2023134725A1 (zh) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种包含神经激肽-1拮抗剂前药化合物的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678317A (zh) * 2002-07-03 2005-10-05 先灵公司 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CN102573475A (zh) * 2009-08-14 2012-07-11 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620989A (en) 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
CA2150951A1 (en) 1992-12-14 1994-06-23 Angus Murray Macleod 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
WO1995019344A1 (en) 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
CN102775401B (zh) 2012-08-15 2015-01-07 青岛农业大学 一种美洛昔康的合成方法
CN108148060B (zh) * 2016-12-05 2020-06-19 四川科伦博泰生物医药股份有限公司 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
CN107383008A (zh) * 2017-08-14 2017-11-24 苏州信恩医药科技有限公司 一种罗拉匹坦的合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678317A (zh) * 2002-07-03 2005-10-05 先灵公司 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CN102573475A (zh) * 2009-08-14 2012-07-11 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Also Published As

Publication number Publication date
EP3991730A4 (en) 2023-08-09
TW202115064A (zh) 2021-04-16
CN113905735B (zh) 2024-03-15
EP3991730A1 (en) 2022-05-04
BR112021026554A2 (pt) 2022-05-24
JP2022539570A (ja) 2022-09-12
KR20220054287A (ko) 2022-05-02
CA3144247A1 (en) 2020-12-30
WO2020259675A1 (zh) 2020-12-30
AU2020308397A1 (en) 2022-02-17
MX2021015827A (es) 2022-04-11
US20220380393A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
TWI828358B (zh) 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法
KR102542199B1 (ko) Glp-1 수용체 작용제 및 이의 용도
CN113905735B (zh) 神经激肽-1拮抗剂
TWI781342B (zh) KEAP1-Nrf2蛋白-蛋白交互作用抑制劑
CN105579444A (zh) 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途
AU2007338700A1 (en) Sphingosine-1 -phosphate receptor agonist and antagonist compounds
JP2011529952A (ja) ジアザインドール誘導体およびｃ−ＪｕｎＮ末端キナーゼの阻害におけるそれらの使用
EA023775B1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EP4247817A1 (en) Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator
CN107148409B (zh) 经取代的二环化合物
KR20230057386A (ko) Apol1 억제제 및 사용 방법
KR102356040B1 (ko) α7니코틴성 아세틸콜린 수용체의 리간드 화합물 및 그 응용
WO2019205979A1 (zh) 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
CN114286822A (zh) 作为pd-1/pd-l1小分子抑制剂的化合物及其应用
CN105121440A (zh) 吡唑并喹啉衍生物的盐及其晶体
WO2020156189A1 (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
WO2023139534A1 (en) Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
CN113272315A (zh) 一类类固醇化合物及其用途
WO2021104413A1 (zh) 稠合吡啶环衍生物、其制备方法及其在医药上的应用
KR20230079111A (ko) 융합된 삼환계 유도체 및 이의 약학적 적용
JP6868008B2 (ja) 疼痛のための治療化合物及びその合成
WO2023187715A1 (en) Complement factor b inhibitors and uses thereof
CN117946112A (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
JPH06135835A (ja) 細胞活性化剤
WO1999024030A1 (en) Novel trienyl compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064843

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220707

Address after: 361026 room 53, floor 1, building A19, Xiamen biomedical industrial park, 2036 wengjiao West Road, Haicang District, Xiamen City, Fujian Province

Applicant after: Fujian Shengdi Pharmaceutical Co.,Ltd.

Applicant after: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Applicant after: Shanghai senhui Pharmaceutical Co.,Ltd.

Applicant after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Address before: 201210 No. 1288, Haike Road, Zhangjiang Town, Pudong New Area, Shanghai

Applicant before: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Applicant before: Shanghai senhui Pharmaceutical Co.,Ltd.

Applicant before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant